Christopher van Dyck, MD
Yale School of Medicine
Christopher van Dyck serves as Co-Chair for the Protocol Evaluation Committee (PEC) and is a member of the Executive Committee for the ACTC. He is also Professor of Psychiatry, Neurology, and Neuroscience and Director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine, and the Project Director for the CT1812 study.
Dr. van Dyck is a graduate of Yale College and Northwestern University Medical School. He completed his residency in psychiatry, fellowship in geriatric psychiatry, and research fellowship in neuroimaging before joining the faculty at Yale.
Dr. van Dyck is a recognized leader in the neuroimaging and therapeutics of Alzheimer’s disease and healthy aging. He is also Principal Investigator on grants from the National Institutes of Health, the pharmaceutical industry, and a number of private foundations and has authored more than 200 papers and reviews. Finally, Dr. van Dyck is extremely committed to advancing the cause of Alzheimer’s patients and their families on the local and national level. As Chairman of the Medical Scientific Advisory Committee for the Connecticut Chapter of the Alzheimer’s Association, he is intimately involved with local program development, advocacy, and education. He received the Alzheimer’s Association’s “Compassion and Cure” Award for 2005 and “Leader in Advancing Research” Award for 2017.